At a glance
ClinicalIndex Comparison RecordPhase 3Not Yet Recruiting· 852 target
Drug / intervention
Tirofiban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravenous Tirofiban Versus Placebo After Delayed Thrombolysis (4.5-24h) in Acute Ischemic Stroke (PEARL-TIRO): A Multicenter, Double-Blind, Double-Dummy, Randomized Controlled Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted Aug 8, 2025·Updated Aug 8, 2025
In Brief
A Phase 3 clinical trial evaluating Tirofiban and Placebo for Acute Ischemic Stroke. Not yet recruiting, targeting 852 participants across 1 site.
Detailed Summary
A multicenter, double-blind, double-dummy, randomized trial evaluating the efficacy and safety of intravenous tirofiban in acute ischemic stroke (AIS) patients without large/medium vessel occlusion, who presented 4.5-24 hours after onset and received intravenous thrombolysis (IVT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesChina
Collaborators--
Timeline
Phase 3Not Yet Recruiting
2026202720282029
First PostedAug 2025
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionDec 2028
Study CompletionMar 2029
First PostedAug 8, 2025
Enrollment StartDec 1, 2025
Primary CompletionDec 1, 2028
Study CompletionMar 1, 2029
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 11 months agoPrimary completion in 2.4 years
Interventions
Tirofibandrug
Tirofiban is administered as a loading dose and continuous intravenous infusion as soon as possible after the randomization.
Placebodrug
Matched placebo will be infused in a similar fashion.